(Q44146158)

30 November 2017

Impact of disease-modifying therapies on the survival of patients with multiple sclerosis in Taiwan, 1997-2008. (English)

1 reference

30 November 2017

Ching-Piao Tsai

1

1 reference

PubMed ID

23861171

30 November 2017

Charles Tzu-Chi Lee

series ordinal

2

1 reference

30 November 2017

1 September 2013

1 reference

Clinical Drug Investigation

30 November 2017

1 reference

30 November 2017

33

1 reference

30 November 2017

9

1 reference

30 November 2017

647-652

1 reference

Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.

30 November 2017

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0108-7

Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0108-7

Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0108-7

A 20-year incidence trend (1989-2008) and point prevalence (March 20, 2009) of multiple sclerosis in Tehran, Iran: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0108-7

Are the prevalence and incidence of multiple sclerosis changing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0108-7

Increasing prevalence and incidence of multiple sclerosis in South East Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0108-7

Epidemiology of multiple sclerosis in Europe: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0108-7

Population-based epidemiological study of neurological diseases in Taiwan: I. Creutzfeldt-Jakob disease and multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0108-7

A population-based survey of multiple sclerosis in Shanghai, China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0108-7

Survival in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0108-7

Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0108-7

Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0108-7

Trends in survival and cause of death in Danish patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0108-7

Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0108-7

Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0108-7

Prevalence and incidence of multiple sclerosis in Salerno (southern Italy) and its province

21 January 2018

1 reference

12 December 2020

The prevalence of multiple sclerosis in 3 US communities

1 reference

12 December 2020

The clinical course of multiple sclerosis patients in Hong Kong.

1 reference

12 December 2020

Multiple sclerosis survival: a population-based study in Sicily

1 reference

12 December 2020

Adherence to multiple sclerosis disease-modifying therapies in Ontario is low

1 reference

12 December 2020

10.1007/S40261-013-0108-7

Identifiers

DOI

1 reference

30 November 2017

1 reference

PubMed ID

23861171